Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study
Open Access
- 8 February 2014
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 5 (1) , 141-153
Abstract
Albiglutide, a selective once-weekly glucagon-like peptide-1 receptor agonist, is being developed for the treatment of type 2 diabetes mellitus. Albiglutide’s effect on cardiac repolarization (QTc interval) was assessed in a randomized, double-blind, placebo-controlled, parallel-group study in healthy subjects with a nested crossover comparison for moxifloxacin.Keywords
This publication has 21 references indexed in Scilit:
- Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjectsBritish Journal of Clinical Pharmacology, 2013
- Daily Dosing of Vismodegib to Steady State Does Not Prolong the Qtc Interval in Healthy VolunteersJournal of Cardiovascular Pharmacology, 2013
- The effect of glucagon-like peptide 1 on cardiovascular riskNature Reviews Cardiology, 2012
- Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double‐blind, placebo‐ and positive‐controlled thorough QT studyBritish Journal of Clinical Pharmacology, 2012
- Population Pharmacokinetic and Concentration-QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT StudiesThe Journal of Clinical Pharmacology, 2011
- The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidanceBritish Journal of Pharmacology, 2010
- Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 DiabetesDiabetes Care, 2009
- Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT intervalHeart Rhythm, 2006
- Spectrum of drugs prolonging QT interval and the incidence of torsades de pointesEuropean Heart Journal Supplements, 2001
- More powerful procedures for multiple significance testingStatistics in Medicine, 1990